Medication recalls, shortages, FDA safety communications, black-box warnings, and practical medication risk updates.
FDA warnings, shortages, recalls, medication risks, safety notices
Prescriptions; Health Insurance; Medical Care
FDA says four lots of cetirizine 5 mg tablets were recalled because of possible ranitidine cross-contamination. Check your lot number, stop if it matches, and call 911 for signs of anaphylaxis.
On June 10, 2026, the FDA approved label updates for OTC alli (orlistat) 60 mg that add clearer warnings about rare but serious kidney risks, including kidney stones. If you have a history of kidney disease or kidney stones, the label advises asking a health care provider before using alli—and stopping alli and seeking medical guidance promptly if symptoms appear.
The FDA updated its safety communication on July 2, 2026, confirming a Class I recall for certain Insulet Omnipod pods. If you use Omnipod, check the pod lot, stop using pods from affected lots, change your pod immediately if yours may be affected, monitor glucose closely, and follow your ketone plan—especially if high blood sugar doesn’t improve.
FDA added a new kidney injury and kidney stone warning to OTC alli on June 10, 2026. This was a label change, not a recall, but some users should check with a clinician before using it.
Usually not. For most patients with an affected Boston Scientific ACCOLADE-family pacemaker or CRT-P, the FDA’s May 7, 2026 Class I recall correction points to software updates and closer monitoring, not automatic urgent replacement.
Probably not automatically. The FDA’s June 10, 2026 label change for alli adds a warning about rare kidney stones and kidney injury, but the practical question is whether you have risk factors or symptoms that mean you should pause and get medical advice.
The FDA’s June 4 Early Alert follows Insulet’s May 26 correction for certain Omnipod pod lots. Here’s how to check your pods, what signs to watch for, and when high blood sugar may need urgent or emergency care.
The FDA says one lot of MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream was recalled because it was contaminated with Staphylococcus aureus. If you use eczema cream or another topical product at home, it is worth checking the label, lot number, and expiration date before you apply it again. Here’s how to tell whether a cream in your medicine cabinet is affected, what contamination can mean for irritated skin, and when skin symptoms should prompt a call to a clinician.
The FDA has proposed withdrawing approval of Tavneos, a drug used with standard treatment for some adults with ANCA-associated vasculitis. The agency says the proposal is not a final removal, and the medicine remains available while the process continues.
The FDA says one lot of MG217 Multi-symptom Treatment Cream & Skin Protectant Eczema Cream is being recalled nationwide because it was contaminated with Staphylococcus aureus. People with weakened immune systems or damaged skin may face the greatest risk, and anyone who used the affected tube should watch for signs of infection and seek care promptly if symptoms appear.
The FDA is warning patients and clinicians about two separate device-safety issues: a Class I recall for certain Omnipod 5 pods and a safety communication about Boston Scientific Accolade pacemakers that may need earlier replacement in some patients. The main takeaway is to verify whether your specific device is affected and follow the official instructions and your care team’s guidance.
B. Braun has recalled two lots of Lactated Ringer’s Injection, 1L, after FDA-posted company testing found particulate matter in the solution. The recall applies to hospitals and healthcare facilities, so patients, caregivers, pharmacists, and clinicians should check lot numbers and follow recall instructions rather than making treatment changes on their own.
The FDA updated its medical device shortage list on March 13, 2026, adding angiographic control syringes with rotating adapters and stereotactic breast biopsy needles. Shortages are not the same as recalls, but they can still affect scheduling, substitutions, and procedure planning.
A federal import plan may ease some Bicillin L-A shortages, but access can still vary. For pregnancy, penicillin remains the only recommended syphilis treatment.
The FDA now requires new warnings on carbidopa/levodopa labels about vitamin B6 deficiency and possible seizures, with advice on testing and monitoring.
FDA’s 2026 GLP-1 crackdown targets compounded or illegally marketed products, not approved brands. Here’s how patients can verify what they’re taking.
With semaglutide and tirzepatide shortages resolved, the FDA is tightening scrutiny of mass-marketed compounded GLP-1s. Here is what changed and what patients should ask now.
The FDA says some telehealth companies used false or misleading marketing for compounded GLP-1 drugs. Here is what that means for patients, how compounded products differ from approved drugs, and what to check before ordering online.
FDA has stepped up action against compounded GLP-1 weight-loss drugs sold online and through telehealth. Here’s what changed in 2026, why the agency says shortages no longer justify broad copycat compounding, what safety problems it has flagged, and how to protect yourself before buying.
FDA says Silintan capsules sold online nationwide contained undeclared meloxicam, an NSAID that can raise the risk of bleeding, ulcers, kidney injury, heart attack, and stroke in some users.
Severe low blood sugar remains a preventable but dangerous complication of diabetes. Updated 2026 guidelines from the American Diabetes Association emphasize broader continuous glucose monitoring, safer medication choices, and ready-to-use glucagon — with important insurance implications for older adults.
Using headache medicines too often can sometimes make headaches worse instead of better. Here’s what U.S. experts say about medication overuse headache—how it happens, who’s at risk, and how to break the cycle safely.
End of content
End of content
